Trial · NCT07026279
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
NCT07026279, Phase 1, Phase 2, Active not recruiting, Amplia Therapeutics Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer. Trials, record NCT07026279. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07026279
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
- NCT number
- NCT07026279
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 67 participants, estimated
- Lead sponsor
- Amplia Therapeutics Limited
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- narmafotinib ascending doses, narmafotinib dose comparison
- First posted
- 2025-06-18
- Last updated
- 2026-05-05
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study | From first dose of study drug to end of study, an expected average of 6 months | TEAEs during study treatment and follow up periods |
| Primary | Part B: identification of optimal dose of narmafotinib | From first dose of study drug to end of study, an expected average of 6 months | The optimal dose will be selected based on a review of safety, pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and any other available relevant data |
| Secondary | narmafotinib levels in plasma | Days -7, -6, -1, 1 and 15 of Run-In/Cycle 1; and Day 1 of Cycles 2 and 4 (each cycle is 28 days) | Measurement of maximum concentration (Cmax) of narmafotinib |
| Secondary | narmafotinib levels in plasma | Days -7, -6, -1, 1 and 15 of Run-In/Cycle 1; and Day 1 of Cycles 2 and 4 (each cycle is 28 days) | Measurement of time to Cmax (tmax) of narmafotinib |
| Secondary | narmafotinib levels in plasma | Days -7, -6, -1, 1 and 15 of Run-In/Cycle 1; and Day 1 of Cycles 2 and 4 (each cycle is 28 days) | Measurement of clearance of narmafotinib |
| Secondary | Overall response rate (ORR) | Imaging every 56 days per participant, with an expected average duration of 6 months | ORR based on RECIST 1.1 |
| Secondary | Overall survival (OS) | Imaging every 56 days per participant, with an expected average duration of 6 months | OS of participants, defined as time from first dose until death from any cause |
| Secondary | Progression free survival (PFS) | Imaging every 56 days per participant, with an expected average duration of 6 months | PFS of participants, defined as time from first dose to date of first observed progression, based on RECIST, or death from any cause (whichever comes first) |
| Secondary | Clinical benefit rate (CBR) | Imaging every 56 days per participant, with an expected average duration of 6 months | CBR defined as the proportion of patients with complete response (CR) + partial response (PR) + stable disease (SD) with SD for at least 6 months |
| Secondary | Duration of response (DOR) | Imaging every 56 days per participant, with an expected average duration of 6 months | DOR based on RECIST defined as the time from the date of the first confirmed response to the date of progression or death |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07026279
GET https://conductscience.org/api/trials/v1/NCT07026279/registered